Analyst Price Targets — INCY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 11:21 am | — | Canaccord Genuity | $152.00 | $128.47 | TheFly | Incyte initiated with a Buy at Canaccord |
| August 17, 2026 11:04 am | Allison Bratzel | Piper Sandler | $130.00 | $120.16 | TheFly | Incyte price target raised to $130 from $110 at Piper Sandler |
| August 13, 2026 11:55 am | — | Bernstein | $104.00 | $120.77 | TheFly | Incyte price target raised to $104 from $99 at Bernstein |
| August 3, 2026 10:10 am | Andrew Berens | Leerink Partners | $155.00 | $119.52 | TheFly | Incyte price target raised to $155 from $131 at Leerink |
| July 29, 2026 1:51 pm | Brian Abrahams | RBC Capital | $109.00 | $126.69 | TheFly | Incyte price target raised to $109 from $99 at RBC Capital |
| July 29, 2026 12:05 pm | — | BMO Capital | $130.00 | $128.83 | TheFly | Incyte price target raised to $130 from $112 at BMO Capital |
| July 29, 2026 11:14 am | Whitney Ljem | Guggenheim | $150.00 | $129.93 | StreetInsider | Incyte (INCY) PT Raised to $150 at Guggenheim |
| July 29, 2026 11:09 am | — | Morgan Stanley | $119.00 | $129.93 | TheFly | Incyte price target raised to $119 from $104 at Morgan Stanley |
| July 29, 2026 9:59 am | — | H.C. Wainwright | $150.00 | $129.93 | TheFly | Incyte price target raised to $150 from $140 at H.C. Wainwright |
| July 29, 2026 9:20 am | — | Barclays | $139.00 | $129.93 | TheFly | Incyte price target raised to $139 from $134 at Barclays |
Latest News for INCY
Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are…
Beacon Pointe Advisors LLC bought a new position in Incyte Corporation (NASDAQ: INCY) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 84,502 shares of the biopharmaceutical company's stock, valued at approximately $9,579,000. Several other large investors have also recently bought and
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin,…
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Analog…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.